The PBYI technology approach is more like Galena Biopharma's ( GALE ) NeuVax technology, which uses the HER2-derived E75 peptide and immune adjuvant granulocyte macrophage colony stimulating factor to induce a targeted "killer" T cell assault on over-expressing cells, going right after root phenomena. In the case of PBYI, they are going straight after signal transduction through the epidermal growth factor receptors (EGFRs, for HER1 and HER4 as well). Efficacy in combination and as a standalone agent is abundantly clear from the clinical trial work and investors should take note of the potential for broad-spectrum Neratinib applicability in the oncology space as a driving factor for future performance of the stock.